8-K: HCA Healthcare Previews Q2 2026 Results, Revises 2026 Guidance

HCA Healthcare announced preliminary Q2 2026 results, anticipating revenue of $20.230 billion and net income of $1.699 billion, while revising its full-year 2026 guidance.

Summary

• HCA Healthcare released preliminary financial and operating results for the second quarter ended June 30, 2026.
• Anticipated revenues for Q2 2026 are approximately $20.230 billion, an increase from $18.605 billion in Q2 2025.
• Expected net income attributable to HCA Healthcare for Q2 2026 is approximately $1.699 billion, or $7.62 per diluted share, up from $1.653 billion, or $6.83 per diluted share, in Q2 2025.
• Adjusted EBITDA for Q2 2026 is projected to be approximately $4.027 billion, compared to $3.849 billion in Q2 2025.
• Same facility admissions increased by 2.5%, equivalent admissions by 2.7%, and emergency room visits by 3.6% in Q2 2026 year-over-year.
• Same facility inpatient and outpatient surgeries declined by 2.3% and 3.4%, respectively, in Q2 2026 compared to Q2 2025.
• The company has revised its full-year 2026 guidance, with revenues now expected between $77.000 billion and $79.500 billion, and net income between $6.300 billion and $6.700 billion.
• The full-year 2026 Adjusted EBITDA guidance has been revised to a range of $15.400 billion to $16.100 billion.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral to slightly negative sentiment due to mixed operational results and a downward revision of full-year guidance, despite some positive year-over-year growth in key metrics.

Positives

• Revenue for Q2 2026 is anticipated to increase to $20.230 billion from $18.605 billion in Q2 2025.
• Net income for Q2 2026 is expected to rise to $1.699 billion ($7.62 per diluted share) from $1.653 billion ($6.83 per diluted share) in Q2 2025.
• Adjusted EBITDA for Q2 2026 is projected to increase to $4.027 billion from $3.849 billion in Q2 2025.
• Same facility admissions grew by 2.5% in Q2 2026 compared to the prior year.
• Same facility equivalent admissions increased by 2.7% in Q2 2026 compared to the prior year.
• Same facility emergency room visits saw a 3.6% increase in Q2 2026 compared to the prior year.
• The company recognized approximately $400 million of incremental net benefit from Medicaid Supplemental Payment Programs in Q2 2026.
• The full-year 2026 revenue guidance range has been narrowed and slightly adjusted upwards at the low end to $77.000 billion to $79.500 billion.

Negatives

• A payer mix shift, driven by an increase in uninsured volume, had an unfavorable impact of approximately $400 million on income before income taxes in Q2 2026.
• Same facility inpatient surgeries declined by 2.3% in Q2 2026 compared to the same period in 2025.
• Same facility outpatient surgeries declined by 3.4% in Q2 2026 compared to the same period in 2025.
• The full-year 2026 net income guidance range has been lowered to $6.300 billion to $6.700 billion from the previous range of $6.495 billion to $7.035 billion.
• The full-year 2026 Adjusted EBITDA guidance range has been lowered to $15.400 billion to $16.100 billion from $15.550 billion to $16.450 billion.
• The full-year 2026 diluted EPS guidance range has been lowered to $28.70 to $30.50 from $29.10 to $31.50.
• The estimated unfavorable impact from health insurance exchanges for the full year 2026 has increased to $1.000 billion to $1.200 billion, from a previous estimate of $600 million to $900 million.

Risks

• Changes in general economic or business conditions nationally and regionally, including inflation and trade policies.
• Impact of current and future health care public policy developments, including changes to federal, state, or local laws and regulations.
• Expiration of enhanced premium tax credits (EPTCs) at the end of 2025 for individuals purchasing insurance through marketplaces.
• Significant indebtedness and the ability to refinance it on acceptable terms.
• Potential reductions or changes in Medicare, Medicaid, and other state programs, including supplemental payment programs.
• Increases in the amount and risk of collectability of uninsured accounts and deductibles.
• Personnel-related capacity constraints, increases in wages, and the ability to attract and retain qualified personnel.
• The highly competitive nature of the health care business and changes in service mix, revenue mix, and service volumes.

Future Outlook

The company has revised its 2026 guidance downwards for net income, Adjusted EBITDA, and diluted EPS, reflecting an increased unfavorable impact from health insurance exchanges and a higher benefit from Medicaid Supplemental Payment Programs. Full-year revenue guidance has been slightly adjusted. Capital expenditure estimates remain unchanged at $5.0 billion to $5.5 billion, excluding acquisitions.

Management Comments

• "Our colleagues continue to manage well through the positive and negative factors that have impacted our business in the first half of the year, and I want to thank them for their great work."
• "As we look to the balance of the year, we have adjusted our guidance to reflect these factors."
• "Moreover, we remain confident in our ability to navigate through this dynamic environment, maintain our focus and investments on improving patient care, and execute on our strategic plan to digitize and grow our healthcare networks."

Industry Context

StockSavvy.ai notes that HCA Healthcare's preliminary Q2 2026 results and revised guidance reflect ongoing industry pressures such as payer mix shifts and evolving reimbursement programs, alongside operational strengths in admissions and ER visits. The adjustments to guidance highlight the dynamic nature of the healthcare landscape and the company's efforts to adapt.

Legal Proceedings

• The filing mentions the potential outcome of pending and any future tax audits, disputes, and litigation associated with tax positions.
• It also notes the impact of known and unknown government investigations, litigation, and other claims that may be made against the company.

Stakeholder Impact

• Shareholders: The downward revision of full-year guidance for net income, Adjusted EBITDA, and EPS may negatively impact investor sentiment and stock price.
• Employees: Management thanks colleagues for their work, implying continued focus on operational execution.
• Patients: Payer mix shifts and increased uninsured volume could impact access to care for certain patient populations.
• Creditors: The company's significant indebtedness is noted as a risk factor, impacting its ability to refinance on acceptable terms.

Next Steps

• HCA Healthcare will host its second quarter earnings call on Friday, July 24, 2026, at 9:00 a.m. Central Time.
• Additional commentary on second quarter earnings will be provided during the earnings call.

Key Dates

Recommendation

The company shows year-over-year growth in key Q2 metrics, but the downward revision of full-year guidance due to increased headwinds from health insurance exchanges and a shift in payer mix warrants a cautious approach. While operational execution remains strong in areas like admissions, the increased uncertainty in the full-year outlook suggests holding the stock until further clarity emerges.

Keywords

HCA Healthcare, Q2 2026 Results, Financial Guidance, Healthcare, Revenue, Net Income, Adjusted EBITDA, Admissions